September 04, 2009, Baltimore , MD. Comprehensive Cancer Cell Diagnostics (CCCD), has launched a CLIA compliant testing laboratory to market the Breast Cancer DirectHit^TM Panel as a diagnostic service. The DirectHit Panel™ Service analyzes an individual patient’s tumor in order to indicate the sensitivity / resistance to FDA-approved, National Comprehensive Cancer Network (NCCN) recommended chemotherapy drugs currently on the market.

The Breast Cancer DirectHit™ Panel is the only predictive treatment outcome test service marketed for commonly prescribed anti-breast cancer chemotherapy drugs. The technology is based on the measurement of biomarker expression levels that are linked to chemotherapy response. The DirectHit™ panel allows physicians to prescribe effective drug treatments, resulting in prolonged patient survival and significant financial savings.

CCCD, a Baltimore, MD. based company, was formed in 2004 by a core group of former Johns Hopkins University researchers whose combined distinguished careers cover 90+ years of leadership in biophysics, oncology and imaging. The company’s mission is to aid physicians in establishing a personalized treatment regime for individual cancer patients. CCCD is dedicated to “saving lives and life savings.” CCCD is located at 3918 Vero Rd , Ste B, Baltimore , MD. The Company URL is www.cccdiag.com and the telephone number is 410-633-4885.

DirectHit™ is a trademark owned by CCCD.